CSI Market
Sign In | Register

Neumora Therapeutics Inc (NMRA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NMRA quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Neumora Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023)
Operating Activities
Income-236.93
Depreciation & amortization0.21
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.60
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.05
Share-based Compensation29.88
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Acquired In Process Research And Development-
Investment Income Net Amortization Of Discount And Premium-
Noncash Operating Lease Expense1.89
Non Cash Interest Expense And Amortization Of Debt Isuance Costs-
Investment Income Amortization Of Discount-2.93
Amortization Of Debt Issuance Costs And Accretion Of Final Payment Fee0.49
Increase Decrease In Operating Lease Liability0.72
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.07
Increase (Decrease) in Accrued Liabilities4.20
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.77
Other Working Capital-0.05
Other Noncash Expense0.03
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.88
Discontinued operations0.00
Net Cash flow from Operating Activities-206.44
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.22
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-82.87
Real Estate Investments0.00
Proceeds From Maturities Of Marketable Securities251.17
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities168.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings57.16
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-325.89
Repurchase Of Unvested Early Exercised Shares-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations143.36
Restricted Cash-
Restricted Cash And Cash Equivalents182.53
Proceeds From Issuance Of Common Stock In At- The- Market Transactions19.65
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities77.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-206.22
Total Cash Flow39.17
4 historic quarters locked

Sign in to unlock the full Neumora Therapeutics Inc cash flow history.

Sign In Create Free Account

About Neumora Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-130388

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License